NPM1 and acute myeloid leukemia: Although differences in survival were not statistically significant within treatment arms compared with the wild-type genes, mutations in NPM1 appeared to confer somewhat poorer survival, in contrast to what has been shown in other AML cohorts [39, 40], in both the azacitidine and CCR treatment arms.